The role of ribociclib in the treatment of early hormone receptor-positive HER2-negative breast cancer: 4-year results of the randomized controlled phase 3 trial NATALEE and their reconsideration for clinical practice

This review presents the relevance of escalating pathogenetic treatment in patients with hormone receptor-positive breast cancer, identifies key goals for prescribing adjuvant combined endocrine therapy with CDK4 / 6 inhibitors in patients with stage II–III breast cancer, and presents 3- and 4-year results of the randomized controlled trial NATALEE. Studies comparing oncological outcomes of “traditional” drug regimens and combined endocrine therapy with ribociclib in patients with similar characteristics are demonstrated. Data on estimating the size of a population of patients with characteristics equivalent to those in the NATALEE trial for prescribing ribociclib in routine practice are presented.